Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Nuvalent Inc Cl A (NUVL)

Nuvalent Inc Cl A (NUVL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 6,731,002
  • Shares Outstanding, K 72,105
  • Annual Sales, $ 0 K
  • Annual Income, $ -260,760 K
  • EBIT $ -398 M
  • EBITDA $ -413 M
  • 60-Month Beta 1.31
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 8.18

Options Overview Details

View History
  • Implied Volatility 68.07% ( +4.95%)
  • Historical Volatility 54.15%
  • IV Percentile 89%
  • IV Rank 68.62%
  • IV High 84.44% on 10/31/25
  • IV Low 32.28% on 01/22/25
  • Put/Call Vol Ratio 0.19
  • Today's Volume 25
  • Volume Avg (30-Day) 68
  • Put/Call OI Ratio 1.16
  • Today's Open Interest 1,896
  • Open Int (30-Day) 1,759

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 17 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -1.51
  • Number of Estimates 7
  • High Estimate -1.41
  • Low Estimate -1.69
  • Prior Year -1.05
  • Growth Rate Est. (year over year) -43.81%

Price Performance

See More
Period Period Low Period High Performance
1-Month
82.50 +13.15%
on 10/08/25
104.90 -11.01%
on 10/30/25
+9.97 (+11.96%)
since 10/07/25
3-Month
71.13 +31.24%
on 08/08/25
104.90 -11.01%
on 10/30/25
+21.19 (+29.37%)
since 08/07/25
52-Week
55.53 +68.09%
on 04/09/25
104.90 -11.01%
on 10/30/25
-0.74 (-0.79%)
since 11/07/24

Most Recent Stories

More News
Nuvalent to Present Patient-Reported Outcomes Data from ARROS-1 Trial of ROS1-Selective Inhibitor, Zidesamtinib, at 2025 IASLC ASCO North America Conference on Lung Cancer

Encore pivotal efficacy and safety data from the ARROS-1 trial also to be presented during poster session

NUVL : 93.35 (-2.63%)
Nuvalent Highlights Recent Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports Third Quarter 2025 Financial Results

Completed rolling NDA submission for zidesamtinib in TKI pre-treated advanced ROS1-positive NSCLC

NUVL : 93.35 (-2.63%)
Nuvalent Presents Preliminary Data for Neladalkib in Advanced ALK-positive Solid Tumors Beyond NSCLC at ESMO 2025

Encouraging preliminary activity observed across diverse set of advanced ALK-positive solid tumors

NUVL : 93.35 (-2.63%)
Stifel Nicolaus Resumes Coverage with a Buy Rating on Nuvalent (NUVL)

In a report released yesterday, Laura Prendergast from Stifel Nicolaus resumed coverage with a Buy rating on Nuvalent and a price target of $115.00. The company’s shares closed yesterday at $89.64.Elevate...

NUVL : 93.35 (-2.63%)
Nuvalent to Present New Preclinical Data for HER2-Selective Inhibitor, NVL-330, at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

CAMBRIDGE, Mass. , Oct. 13, 2025 /PRNewswire/ --  Nuvalent, Inc.  (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating  precisely  targeted therapies for clinically...

NUVL : 93.35 (-2.63%)
Nuvalent to Participate in the UBS 2025 Virtual Oncology Day

CAMBRIDGE, Mass. , Sept. 24, 2025 /PRNewswire/ -- Nuvalent, Inc.  (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating  precisely  targeted therapies...

NUVL : 93.35 (-2.63%)
Nuvalent Presents Pivotal Data from ARROS-1 Clinical Trial of Zidesamtinib for TKI Pre-treated Patients with Advanced ROS1-positive NSCLC at WCLC 2025

Rolling NDA submission for zidesamtinib in TKI pre-treated advanced ROS1-positive NSCLC initiated under FDA's RTOR program, with completion on track for the third quarter of 2025

NUVL : 93.35 (-2.63%)
Nuvalent to Participate in the Cantor Global Healthcare Conference 2025

CAMBRIDGE, Mass. , Aug. 28, 2025 /PRNewswire/ --  Nuvalent, Inc.  (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating  precisely  targeted therapies...

NUVL : 93.35 (-2.63%)
Nuvalent to Present Pivotal Data from ARROS-1 Clinical Trial of Zidesamtinib for TKI Pre-treated Patients with Advanced ROS1-positive NSCLC at WCLC 2025 Presidential Symposium

CAMBRIDGE, Mass. , Aug. 13, 2025 /PRNewswire/ --  Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating  precisely  targeted...

NUVL : 93.35 (-2.63%)
Nuvalent Highlights Pipeline and Business Achievements, Reiterates Key Anticipated Milestones, and Reports Second Quarter 2025 Financial Results

Initiated rolling NDA submission for zidesamtinib for TKI pre-treated patients with advanced ROS1-positive NSCLC, with target completion in the third quarter of 2025

NUVL : 93.35 (-2.63%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Nuvalent Inc. is a biopharmaceutical company. It focused on creating precisely targeted therapies for clinically proven kinase targets in cancer. The company's program pipeline includes ROS1-positive and ALK-positive NSCLC. Nuvalent Inc. is based in CAMBRIDGE, Mass.

See More

Key Turning Points

3rd Resistance Point 99.79
2nd Resistance Point 97.84
1st Resistance Point 95.60
Last Price 93.35
1st Support Level 91.41
2nd Support Level 89.46
3rd Support Level 87.22

See More

52-Week High 104.90
Last Price 93.35
Fibonacci 61.8% 86.04
Fibonacci 50% 80.22
Fibonacci 38.2% 74.39
52-Week Low 55.53

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar